Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chengdu Shangli Aesthetic
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Chengdu Shangli Aesthetic holds exclusive rights in China for high-end injectable hyaluronic acid gel products from Humedix (Korea), currently under clinical registration, and is developing recombinant collagen products in partnership with top academic centers. Its parent company is actively building a closed loop of research, production, and sales in premium aesthetic injectables.
- Therapeutic areas
- DermatologyOther
- Modalities
- BiologicProtein
- Industry
- Biotech
02
Partnerships
Humedix (Korea): exclusive China rights for injectable HA gelAcademic collaborations with Zhejiang University International Science and Innovation Center
Beyond the preview
Go deeper on Chengdu Shangli Aesthetic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Shangli Aesthetic.